Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.26470 http://scihub22266oqcxt.onion/10.1002/jmv.26470 32856728!7461283!32856728     free     free     free       J+Med+Virol 2021 ; 93 (3): 1276-1287 Nephropedia Template TP {{tp|p=32856728|t=2021. Management of SARS-CoV-2 pneumonia |pdf=|usr=}}{{32856728}} gab.com Text Management of SARS-CoV-2 pneumonia JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32856728 #FOAvip Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread throughout the world since December 2019 to become a global public health emergency for the elevated deaths and hospitalizations in Intensive Care Units. The severity spectrum of SARS-CoV-2 pneumonia ranges from mild to severe clinical conditions. The clinical course of SARS-CoV-2 disease is correlated with multiple factors including host characteristics (genetics, immune status, age, and general health), viral load and, above all, the host distribution of the airways and lungs of the viral receptor cells. In this review, we will briefly summarize the current knowledge of the characteristics and management of coronavirus disease 2019-pneumonia. However, other studies are needed to better understand the pathogenetic mechanisms induced by SARS-Cov-2 infection, and to evaluate the long-term consequences of the virus on the lungs. Twit Text FOAVip Management of SARS-CoV-2 pneumonia ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32856728 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32856728 #FOAvip English Wikipedia <ref>{{Cite pmid|32856728}}</ref> Management of SARS-CoV-2 pneumonia #MMPMID32856728 Sagnelli C; Celia B; Monari C; Cirillo S; De Angelis G; Bianco A; Coppola N J Med Virol 2021[Mar]; 93 (3): 1276-1287 PMID32856728show ga Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread throughout the world since December 2019 to become a global public health emergency for the elevated deaths and hospitalizations in Intensive Care Units. The severity spectrum of SARS-CoV-2 pneumonia ranges from mild to severe clinical conditions. The clinical course of SARS-CoV-2 disease is correlated with multiple factors including host characteristics (genetics, immune status, age, and general health), viral load and, above all, the host distribution of the airways and lungs of the viral receptor cells. In this review, we will briefly summarize the current knowledge of the characteristics and management of coronavirus disease 2019-pneumonia. However, other studies are needed to better understand the pathogenetic mechanisms induced by SARS-Cov-2 infection, and to evaluate the long-term consequences of the virus on the lungs. |*COVID-19 Drug Treatment[MESH] |Acute Lung Injury/drug therapy/pathology/physiopathology[MESH] |Anti-Inflammatory Agents/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19/pathology/physiopathology[MESH] |Disease Management[MESH] |Humans[MESH] |Lung/diagnostic imaging/pathology[MESH]Management of SARS-CoV-2 pneumonia (epmc).pdf DeepDyve Pubget Overpricing